Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital

被引:18
|
作者
Namikawa, Hiroki [1 ,2 ]
Yamada, Koichi [1 ]
Fujimoto, Hiroki [1 ]
Oinuma, Ken-Ichi [3 ]
Tochino, Yoshihiro [2 ]
Takemoto, Yasuhiko [2 ]
Kaneko, Yukihiro [3 ]
Shuto, Taichi [2 ]
Kakeya, Hiroshi [1 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Infect Control Sci, Osaka, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Med Educ & Gen Practice, Osaka, Japan
[3] Osaka City Univ, Grad Sch Med, Dept Bacteriol, Osaka, Japan
关键词
Escherichia coli; extended-spectrum beta-lactamase; bacteremia; quinolones; immunosuppressive drug; MEDIATED QUINOLONE RESISTANCE; GRAM-NEGATIVE BACTERIA; PIPERACILLIN-TAZOBACTAM; RISK-FACTORS; ENTEROBACTERIACEAE; THERAPY; INFECTIONS; OUTCOMES; MULTICENTER; EMERGENCE;
D O I
10.2169/internalmedicine.56.7702
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective In recent years, infection caused by extended-spectrum beta-lactamase (ESBL)-producing organisms has become an important issue. However, comparative studies of the bacteremia caused by ESBL Enterobacteriaceae and non-ESBL Enterobacteriaceae are extremely rare in Japan. This study aimed to assess the risk factors and prognosis of patients with bacteremia due to ESBL Escherichia coli (E. coli). Methods The medical records of 31 patients with ESBL E. coli bacteremia and 98 patients with non-ESBL E. coli bacteremia who had been admitted to Osaka City University Hospital between January 2011 and June 2015 were retrospectively reviewed. The patient backgrounds, risk factors for infection, and prognosis were evaluated. Results The male-to-female ratio, mean age, underlying disease, leukocyte count, and C-reactive protein (CRP) level did not differ between the patients in the ESBL E. coli bacteremia and non-ESBL E. coli bacteremia groups. The mean Sequential Organ Failure Assessment (SOFA) score for patients with ESBL and non-ESBL E. coli bacteremia were 3.6 and 3.8, respectively. Further, the mortality did not differ between the two groups (9.7% vs 9.2%). However, the independent predictors associated with ESBL E. coli bacteremia according to a multivariate analysis were the use of immunosuppressive drugs or corticosteroids (p=0.048) and quinolones (p= 0.005) prior to isolation. The mortality did not differ between the carbapenem and tazobactam/piperacillin (TAZ/PIPC) or cefmetazole (CMZ) groups for the patients with ESBL E. coli bacteremia. Conclusion Whenever we encountered patients with a history of immunosuppressive drug, corticosteroid, quinolone administration, it was necessary to perform antibiotic therapy while keeping the risk of ESBL E. coli in mind.
引用
收藏
页码:1807 / 1815
页数:9
相关论文
共 50 条
  • [21] Therapeutic Options for Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli
    Tarchini, Giorgio
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (01) : 119 - 120
  • [22] Phenotypic and Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Bangladesh
    Lina, Taslima T.
    Khajanchi, Bijay K.
    Azmi, Ishrat J.
    Islam, Mohammad Aminul
    Mahmood, Belal
    Akter, Mahmuda
    Banik, Atanu
    Alim, Rumana
    Navarro, Armando
    Perez, Gabriel
    Cravioto, Alejandro
    Talukder, Kaisar A.
    [J]. PLOS ONE, 2014, 9 (10):
  • [23] Long-term carriage of extended-spectrum beta-lactamase-producing Escherichia coli
    Alsterlund, Rolf
    Axelsson, Carolina
    Olsson-Liljequist, Barbro
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 44 (01) : 51 - 54
  • [24] Extended-spectrum beta-lactamase-producing Enterobacteriaceae at Middlemore Hospital
    Briggs, Simon
    Ussher, James
    Taylor, Susan
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2005, 118 (1218)
  • [25] Phenotypic and genotypic characterizations of extended-spectrum beta-lactamase-producing Escherichia coli in Thailand
    Bubpamala, Jiranun
    Khuntayaporn, Piyatip
    Thirapanmethee, Krit
    Montakantikul, Preecha
    Santanirand, Pitak
    Chomnawang, Mullika T.
    [J]. INFECTION AND DRUG RESISTANCE, 2018, 11 : 2151 - 2157
  • [26] Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli
    Bishara, J
    Livne, G
    Ashkenazi, S
    Levy, I
    Pitlik, S
    Ofir, O
    Lev, B
    Samra, Z
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2005, 7 (05): : 298 - 301
  • [27] Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing Escherichia coli
    Al-Tamimi, Mohammad
    Abu-Raideh, Jumana
    Albalawi, Hadeel
    Shalabi, Marwan
    Saleh, Saiel
    [J]. MICROBIAL DRUG RESISTANCE, 2019, 25 (08) : 1132 - 1141
  • [28] The clinical impact of sputum isolation of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
    Shikata, Maki
    Iwanaga, Naoki
    Nagayoshi, Yosuke
    Takemoto, Shinnosuke
    Oono, Tadayoshi
    Hisatomi, Keiko
    Nagashima, Seiji
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S209 - S209
  • [29] Prevalence and antibiotic resistance pattern of extended-spectrum beta-lactamase-producing Escherichia coli in clinical specimens
    Shirani, Kiana
    Seydayi, Elahe
    Boroujeni, Kiarash Salimi
    [J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2019, 24
  • [30] Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
    Lo, Ching-Lung
    Lee, Ching-Chi
    Li, Chia-Wen
    Li, Ming-Chi
    Hsueh, Po-Ren
    Lee, Nan-Yao
    Ko, Wen-Chien
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2017, 50 (03) : 355 - 361